Articles with public access mandates - Sarina A. Piha-Paul, MDLearn more
Not available anywhere: 8
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ...
Nature medicine 29 (1), 115-126, 2023
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase …
S Cousin, JY Blay, IB Garcia, JS de Bono, C Le Tourneau, V Moreno, ...
International journal of cancer 150 (6), 993-1006, 2022
Mandates: US National Institutes of Health, National Institute for Health Research, UK …
Safety and tolerability of MEDI0562, an OX40 agonist mAb, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors
JW Goldman, SA Piha-Paul, B Curti, KS Pedersen, TM Bauer, ...
Clinical Cancer Research 28 (17), 3709-3719, 2022
Mandates: US National Institutes of Health
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer
R Said, Y Ye, DS Hong, A Naing, G Falchook, S Fu, JJ Wheler, ...
Cancer chemotherapy and pharmacology 77, 575-581, 2016
Mandates: US National Institutes of Health
Pembrolizumab in patients with refractory cutaneous squamous cell carcinoma: a phase II trial
R Ferrarotto, LG Sousa, Y Qing, D Kaya, B Stephen, D Jain, D Bell, S Pant, ...
Advances in Therapy 38 (8), 4581-4591, 2021
Mandates: US National Institutes of Health
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and …
E Fountzilas, E Krishnan, F Janku, S Fu, DD Karp, A Naing, V Subbiah, ...
Cancer chemotherapy and pharmacology 82, 877-885, 2018
Mandates: US National Institutes of Health
Toxicity in 1,181 patients with advanced solid tumors treated in phase I clinical trials of predominantly targeted agents: The MD Anderson Cancer Center experience.
JJ Wheler, AM Tsimberidou, S Wen, A Naing, DS Hong, GS Falchook, ...
Journal of Clinical Oncology 28 (15_suppl), 2604-2604, 2010
Mandates: US National Institutes of Health
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
O Alhalabi, AW Hahn, P Msaouel, F Meric-Bernstam, N Wilson, A Naing, ...
Clinical Genitourinary Cancer 20 (1), e16-e24, 2022
Mandates: US Department of Defense, US National Institutes of Health
Available somewhere: 173
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study
A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ...
Journal of Clinical Oncology 38 (1), 1-10, 2020
Mandates: US National Institutes of Health
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
Mandates: US National Institutes of Health
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ...
Clinical cancer research 18 (22), 6373-6383, 2012
Mandates: US National Institutes of Health
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
D Hong, R Kurzrock, Y Kim, R Woessner, A Younes, J Nemunaitis, ...
Science translational medicine 7 (314), 314ra185-314ra185, 2015
Mandates: US National Institutes of Health
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
F Janku, AM Tsimberidou, I Garrido-Laguna, X Wang, R Luthra, DS Hong, ...
Molecular cancer therapeutics 10 (3), 558-565, 2011
Mandates: US National Institutes of Health
Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials
F Meric-Bernstam, L Brusco, K Shaw, C Horombe, S Kopetz, MA Davies, ...
Journal of clinical oncology 33 (25), 2753-2762, 2015
Mandates: US National Institutes of Health
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE‐158 and KEYNOTE‐028 studies
SA Piha‐Paul, DY Oh, M Ueno, D Malka, HC Chung, A Nagrial, RK Kelley, ...
International journal of cancer 147 (8), 2190-2198, 2020
Mandates: US National Institutes of Health
Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies
HC Chung, SA Piha-Paul, J Lopez-Martin, JHM Schellens, S Kao, ...
Journal of Thoracic Oncology 15 (4), 618-627, 2020
Mandates: US National Institutes of Health
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
F Janku, JJ Wheler, A Naing, GS Falchook, DS Hong, VM Stepanek, S Fu, ...
Cancer research 73 (1), 276-284, 2013
Mandates: US National Institutes of Health
Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer
F Meric-Bernstam, AM Johnson, EEI Dumbrava, K Raghav, K Balaji, ...
Clinical Cancer Research 25 (7), 2033-2041, 2019
Mandates: US National Institutes of Health
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
F Janku, DS Hong, S Fu, SA Piha-Paul, A Naing, GS Falchook, ...
Cell reports 6 (2), 377-387, 2014
Mandates: US National Institutes of Health
Cancer therapy directed by comprehensive genomic profiling: a single center study
JJ Wheler, F Janku, A Naing, Y Li, B Stephen, R Zinner, V Subbiah, S Fu, ...
Cancer research 76 (13), 3690-3701, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program